Axogen, Inc. (AXGN) News
Filter AXGN News Items
AXGN News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
AXGN News Highlights
- AXGN's 30 day story count now stands at 8.
- Over the past 20 days, the trend for AXGN's stories per day has been choppy and unclear. It has oscillated between 1 and 2.
- The most mentioned tickers in articles about AXGN are BEAT, NOV and DYNT.
Latest AXGN News From Around the Web
Below are the latest news stories about AXOGEN INC that investors may wish to consider to help them evaluate AXGN as an investment opportunity.
Axogen, Inc. to Participate at the Piper Sandler 35th Annual Healthcare ConferenceALACHUA and TAMPA, Fla., Nov. 20, 2023 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, today announced that Karen Zaderej, Chairman, Chief Executive Officer, and President, will present at the Piper Sandler 35th Annual Healthcare Conference in New York, NY, on Thursday, November 30, 2023, at 8:50 a.m. E.T. Webcast events can be accessed live through the Investors page at www.axogeninc.com. F |
Great week for AxoGen, Inc. (NASDAQ:AXGN) institutional investors after losing 51% over the previous yearKey Insights Institutions' substantial holdings in AxoGen implies that they have significant influence over the... |
AxoGen, Inc. (NASDAQ:AXGN) Q3 2023 Earnings Call TranscriptAxoGen, Inc. (NASDAQ:AXGN) Q3 2023 Earnings Call Transcript November 7, 2023 AxoGen, Inc. beats earnings expectations. Reported EPS is $0.01, expectations were $-0.08. Operator: Greetings. Welcome to the AxoGen Reports Third Quarter 2023 Financial Results. At this time, all participants are in a listen-only mode. A question-and-answer session will follow the formal presentation. [Operator Instructions] […] |
Q3 2023 AxoGen Inc Earnings CallQ3 2023 AxoGen Inc Earnings Call |
Axogen Inc (AXGN) Reports 12% Revenue Growth in Q3 2023Despite a Net Loss of $4.1 Million, the Company Sees Improvement in Emergent Trauma Category and Continued Strength in Scheduled Procedures |
Axogen, Inc. Reports 2023 Third Quarter Financial ResultsALACHUA, Fla. and TAMPA, Fla., Nov. 07, 2023 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, today reported financial results and business highlights for the third quarter ended September 30, 2023. Third Quarter Financial Results Revenue was $41.3 million during the third quarter, an increase of approximately 12% over the third quarter of 2022.The Company estimates that revenues from emergen |
Dynatronics Corporation (DYNT) Expected to Beat Earnings Estimates: What to Know Ahead of Q1 ReleaseDynatronics Corporation (DYNT) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations. |
AxoGen (AXGN) Expected to Beat Earnings Estimates: Can the Stock Move Higher?AxoGen (AXGN) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations. |
Axogen, Inc. to Report Third Quarter 2023 Financial Results and Host Conference Call on November 7, 2023ALACHUA, Fla. and TAMPA, Fla., Oct. 18, 2023 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, today announced that it will report third quarter 2023 financial results on Tuesday, November 7, 2023 before the market opens. Axogen management will host an investment-community conference call and webcast at 8:00 a.m. ET following the release. Investors interested in participating in the conference |
AxoGen (AXGN) Moves 6.8% Higher: Will This Strength Last?AxoGen (AXGN) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term. |